MEDROGESTONE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H32O2
Molecular Weight	340.499
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)[C@@]1(C)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChIKey=HCFSGRMEEXUOSS-JXEXPEPMSA-N

InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903
Curator's Comment: description was created based on several sources, including http://www.cngof.asso.fr/d_livres/1996_GO_157_laurent.pdf

Medrogestone is a progesterone derivative used for the treatment of progesterone deficiency, especially those observed in the premenopausal period, haemorrhages and menorrhagia of fibroids, endometriosis, menstrual cycle disorders, etc. The drug acts by binding and activating progesterone receptors. In Europe, medrogestone is available under the name Colprone, however it is no longer marketed in the USA, Germany and Austria.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4288903	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Progesterone deficiency 1 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8583	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Dysmenorrhea 9 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8583	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Endometriosis 32 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Palliative	Approved 8583	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Menstrual cycle disorder 5 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8583	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.
Functional haemorrhages and menorrhagia of fibroids 1 Sources: http://document-rcp.vidal.fr/64/d6a23eedda9d4efcaa39f43b73f22b64.pdf	Primary	Approved 8583	COLPRONE Approved Use Disorders related to progesterone deficiency and especially those observed in the premenopausal period (menstrual irregularities, premenstrual syndrome, mastodynia ...); Functional haemorrhages and menorrhagia of fibroids; Endometriosis; Artificial cycle in combination with estrogen; Dysmenorrhea.

C_max

Value	Dose	Co-administered	Analyte	Population
8.21 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9766865/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MEDROGESTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
98.05 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9766865/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MEDROGESTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
34.95 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9766865/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		MEDROGESTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
15 mg 2 times / day multiple, oral Highest studied dose Dose: 15 mg, 2 times / day Route: oral Route: multiple Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/	unhealthy Health Status: unhealthy Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/	Other AEs: Hypertension, abnormal glucose toleranc... Other AEs: Hypertension (1 pt) abnormal glucose toleranc (1 pt) Impotence (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/

AEs

AE	Significance	Dose	Population
Hypertension	1 pt	15 mg 2 times / day multiple, oral Highest studied dose Dose: 15 mg, 2 times / day Route: oral Route: multiple Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/	unhealthy Health Status: unhealthy Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/
Impotence	1 pt	15 mg 2 times / day multiple, oral Highest studied dose Dose: 15 mg, 2 times / day Route: oral Route: multiple Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/	unhealthy Health Status: unhealthy Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/
abnormal glucose toleranc	1 pt	15 mg 2 times / day multiple, oral Highest studied dose Dose: 15 mg, 2 times / day Route: oral Route: multiple Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/	unhealthy Health Status: unhealthy Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1097740/

PubMed

Title	Date	PubMed
Breast cancer and steroid metabolizing enzymes: the role of progestogens.	2009-12	19962254
Presence of steroid hormones and antibiotics in surface water of agricultural, suburban and mixed-use areas.	2009-07	18568409
Progestins in the menopause in healthy women and breast cancer patients.	2009-04-20	19179024
Estrogen sulfotransferases in breast and endometrial cancers.	2009-02	19250196
Correlation of estrogen sulfotransferase activity and proliferation in normal and carcinomatous human breast. A hypothesis.	2007-11-01	17970064
Progestins and breast cancer.	2007-10	17943537
Free synthetic and natural estrogen hormones in influent and effluent of three municipal wastewater treatment plants.	2007-09	17910365
Colon cancer risk and different HRT formulations: a case-control study.	2007-05-08	17488513
Oral progestagens before menopause and breast cancer risk.	2007-03-12	17299388
Breast cancer risk associated with different HRT formulations: a register-based case-control study.	2006-09-12	16965641
Effects of hormone replacement therapy on the main fatty acids of serum and phospholipids of postmenopausal women.	2005-11-10	16277026
Age-related cognitive decline in the menopause: effects of hormone replacement therapy on cognitive event-related potentials.	2005-07-16	15978969
Influence of different HRT regimens on mammographic density.	2005-02-14	15653007
Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.	2005-02	15860265
The selective estrogen enzyme modulators in breast cancer: a review.	2004-06-07	15172700
Differential effects of progestins on breast tissue enzymes.	2003-12-10	14670645
Androgens and antiandrogens.	2003-11	14644837
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.	2002-12-10	12468135
[Tibolone].	2002-09-07	12355994
Risk of calcium oxalate nephrolithiasis in postmenopausal women supplemented with calcium or combined calcium and estrogen.	2002-02-26	11836046
Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women.	2002-02-26	11836044
Biological effects of progestins in breast cancer.	2001-12	12227886
Cyclic progestin therapy for the management of mastopathy and mastodynia.	2001-12	12227885
The selective estrogen enzyme modulator (SEEM) in breast cancer.	2001-06-01	11384867
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.	2001-05	11334901
Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control.	2001-02	11344825

Patents

Sample Use Guides

In Vivo Use Guide

Take two tablets (10 mg) per day.

Route of Administration: Oral

In Vitro Use Guide

T-47D cells were incubated with medrogestone for 24h and the drug inhibited 17beta-hydroxysteroid dehydrogenase activity in a dose-dependent manner by 39% and 80% at 5 x 10(-8) M and 5 x 10(-5) M.

Name

Type

Language

COLPRO

Preferred Name

English

MEDROGESTONE

Official Name

English

MEDROGESTONE [USAN]

Common Name

English

NSC-123018

Code

English

MEDROGESTONE [MI]

Common Name

English

AY-13615

Code

English

PREGNA-4,6-DIENE-3,20-DIONE, 6,17-DIMETHYL-

Systematic Name

English

AY-62022

Code

English

METROGESTONE

Common Name

English

AY 62022

Code

English

PROTHIL

Brand Name

English

AY-13615S

Code

English

MEDROGESTERONE

Common Name

English

medrogestone [INN]

Common Name

English

6,17-Dimethylpregna-4,6-diene-3,20-dione

Systematic Name

English

Medrogestone [WHO-DD]

Common Name

English

COLPRONE

Brand Name

English

ETOGYN

Brand Name

English

MEDROGESTONE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G03DB03